Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 27;15(4):217-231.
doi: 10.1038/nrmicro.2016.193. Online ahead of print.

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Mark C Field  1 , David Horn  1 , Alan H Fairlamb  1 , Michael A J Ferguson  1 , David W Gray  1 , Kevin D Read  1 , Manu De Rycker  1 , Leah S Torrie  1 , Paul G Wyatt  1 , Susan Wyllie  1 , Ian H Gilbert  1
Affiliations
Review

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Mark C Field et al. Nat Rev Microbiol. .

Erratum in

Abstract

The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them. In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled. In addition, we consider the important challenges to drug discovery strategies and the new technologies that can address them. The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors declare no conflicts of interest.

Figures

Figure for Box 1
Figure for Box 1
Figure 1
Figure 1. The drug discovery process.
Drug discovery progresses through several stages and each stage involves specific steps and regulations. The failure rate at each stage is high, which underscores the need for an active pipeline of drug discovery projects.
Figure 2
Figure 2. Antitrypanosomatid compounds currently in preclinical and clinical development.
a | Several compounds are currently in preclinical and clinical development for human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas’ disease (CD). b | Antitrypansomatid compounds identified through phenotypic approaches that have been progressed into clinical trials.
Figure 3
Figure 3. Molecular targets in trypanosomatids.
a | trypanosomatids show unique metabolic pathways and cellular functions that are attractive for drug discovery. Many enzymes are divergent from other eukaryotes and they have unique or highly specialized organelles such as the kinetoplast and the glycosome, respectively. b | For some antitrypansomatid compounds the molecular targets are known. DDD85646 targets N-myristoyltransferase (NMT); posaconazole and ravuconazole are CYP51 inhibitors; K777 irreversibly inhibits the cysteine protease cruzipain; and GNF6702 selectively inhibits the trypanosomatid proteasome.
Figure 4
Figure 4. Phenotypic approaches to discover antitrypanosomatid compounds.
Various lifecycle stages can be used for the purpose of hit discovery that range from insect forms to host-stage forms in animal models. The different technologies that can be used for phenotypic assays depend on the parasite form and stage and have specific advantages and disadvantages. Examples of compounds whose antitrypanosomal activity was detected using insect forms, in vitro host-stage forms and animal models are shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCall LI, McKerrow JH. Determinants of disease phenotype in trypanosomatid parasites. Trends Parasitol. 2014;30:342–349. - PubMed
    1. WHO. Investing to overcome the global impact of neglected tropical diseases: Third WHO report on neglected diseases. World Health Organisation; 2015.
    1. Dias JC. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas’ disease. Historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz. 2007;102(Suppl 1):11–18. - PubMed
    1. Khyatti M, et al. Infectious diseases in North Africa and North African immigrants to Europe. Eur J Public Health. 2014;24(Suppl 1):47–56. - PubMed
    1. Gilbert IH. Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter. Parasitology. 2014;141:28–36. - PMC - PubMed